Compare MAA & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAA | NBIX |
|---|---|---|
| Founded | 1977 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 15.2B |
| IPO Year | 1994 | 1996 |
| Metric | MAA | NBIX |
|---|---|---|
| Price | $132.64 | $133.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 21 |
| Target Price | $154.83 | ★ $177.05 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 02-04-2026 | 02-05-2026 |
| Dividend Yield | ★ 4.56% | N/A |
| EPS Growth | 6.34 | ★ 12.44 |
| EPS | ★ 4.71 | 4.19 |
| Revenue | $2,203,402,000.00 | ★ $2,682,700,000.00 |
| Revenue This Year | $1.82 | $23.68 |
| Revenue Next Year | $2.02 | $18.47 |
| P/E Ratio | ★ $28.47 | $31.65 |
| Revenue Growth | 0.92 | ★ 19.61 |
| 52 Week Low | $125.75 | $84.23 |
| 52 Week High | $173.38 | $160.18 |
| Indicator | MAA | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 33.49 |
| Support Level | $134.19 | $134.20 |
| Resistance Level | $139.15 | $142.16 |
| Average True Range (ATR) | 2.56 | 2.92 |
| MACD | -0.65 | -1.12 |
| Stochastic Oscillator | 2.37 | 8.52 |
Mid-America Apartment Communities Inc or MAA, is a real estate investment trust engaged in the acquisition, operation, and development of multifamily apartment communities located in the southeastern and southwestern United States. The company operates two reportable segments; Same Store includes communities that the Company has owned and have been stabilized for at least a full 12 months as of the first day of the calendar year and Non-Same Store and Other includes recently acquired communities, communities being developed or in lease-up, communities that have been disposed of or identified for disposition, communities that have experienced a casualty loss and stabilized communities that do not meet the requirements to be Same Store communities.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.